{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dopamine
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.
Class (Stereo):
CHEMICAL (RACEMIC)
ISOSULPRIDE, a benzamide derivative, is an atypical neuroleptic.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mesulergine, an antagonist of 5-HT2C, and dopamine receptors was studied in clinical trials for the treatment of Parkinson's disease. However, further, development was discontinued due to toxicological observations in animal experiments.
Class (Stereo):
CHEMICAL (ACHIRAL)
The benzisoxazolyl piperidine derivative and atypical antipsychotic abaperidone [FI 8602] is being developed by Ferrer for the treatment of schizophrenia. Abaperidone is a potent antagonist of 5-HT2A receptor and dopamine D2 receptor with IC50s of 6.2 and 17 nM.
Status:
Investigational
Source:
INN:lensiprazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lensiprazine (SLV314) is a potent D2 receptor antagonist in vitro and have a considerable in vitro affinity for serotonin reuptake sites. It capable of antagonizing apomorphine-induced climbing behavior, disrupting CAR activity and potentiating 5-hydroxytryptophan (5-HTP) behavior. SLV314 has also been found to antagonize amphetamine- and ketamine-stimulated locomotor activity and methylphenidate-induced gnawing and stimulated behaviors, furthermore, a significant dose discrepancy was seen between the antipsychotic and cataleptogenic effects of SLV314. Lensiprazine demonstrated putative antipsychotic and selective serotonin reuptake inhibitor potential.
Status:
Investigational
Source:
NCT00273416: Phase 2 Interventional Completed Impotence
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Pinoxepin belongs to the dibenzoxepine series of drugs which are characterized by a 6-7-6 tricyclic nuclear structure. Clinical studies indicated that pinoxepin was a potent antipsychotic-sedative equally effective to chlorpromazine and thioridazine. Pinoxepin in studies with chronic schizophrenic patients displayed useful effects on behavior without unduly prominent side effects. In doses above 300 mg seizures are reported and more frequent changes in liver-function tests were noted than with standard drug, but below 300 mg pinoxepin was found to have side effects similar to chlorpromazine and marked sedative effects.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Proterguride is a highly potent dopamine receptor agonist with a long duration of action patented by Schering A.-G. for the treatment of Parkinsonism, restless leg syndrome, or the prophylaxis of migraine. According to preclinical studies, Proterguride, unlike most dopamine receptor agonist, is suitable for transdermal administration. Especially in the case of dopamine agonists, the transdermal route of administration might become of great clinical importance due to the ability to achieve constant plasma levels and, thus, to imitate the physiological continuous release profile of dopamine. Pulsatile stimulation of dopaminergic receptors as it occurs with oral administration of dopaminergic drugs is considered the cause of treatment-associated motor complications.
Class (Stereo):
CHEMICAL (ACHIRAL)
Citatepine is an antagonist of dopamine receptors. It attenuated dopamine-agonist induced behavioral stimulation (stereotypies in rats or climbing in mice). The compound displayed preferential action on hippocampal DA receptors as compared to the striatum. In addition, it shows antihistaminergic, antiserotonergic, anticholinergic and adrenolytic effects. The drug was investigated in the clinic for the treatment of schizophrenia. It was expected that this drug would show an antipsychotic efficacy in doses not causing extrapyramidal side-effects. This expectation has not been fulfilled.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cinuperone is an antagonist of D2, alpha1 adrenergic and sigma receptors. The drug selectively inhibits dopamine agonists-dependent behaviors, mediated by the limbic system. The clinical development of the drug as an antipsychotic was terminated due to orthostasis.
